Terms: = Pancreatic cancer AND FANCA, MGC75158, 2175, ENSG00000187741, FA-H, FA, FAA, FANCH, FA1, FACA AND Treatment
52 results:
1. Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: a multicenter study in Taiwan.
Cheng SM; Su YY; Chiang NJ; Wang CJ; Chao YJ; Huang CJ; Tsai HJ; Chen SH; Chang CY; Tsai CR; Li YJ; Yen CJ; Chuang SC; Chang JS; Shan YS; Hwang DY; Chen LT
J Biomed Sci; 2024 Feb; 31(1):21. PubMed ID: 38350919
[TBL] [Abstract] [Full Text] [Related]
2. Study the Anticancer Properties of Thymol-Loaded PEGylated Bovine Serum Albumin Nanoparticles Conjugated with Folic Acid.
Al-Salih MYA; Pouresmaeil V; Davoodi-Dehaghani F; Haghighi HN; Tabrizi MH
Chem Biodivers; 2023 Nov; 20(11):e202301122. PubMed ID: 37823866
[TBL] [Abstract] [Full Text] [Related]
3. Disulfiram enhances the antitumor activity of cisplatin by inhibiting the Fanconi anemia repair pathway.
Yuan M; Wu Q; Zhang M; Lai M; Chen W; Yang J; Jiang L; Cao J
J Zhejiang Univ Sci B; 2023 Mar; 24(3):207-220. PubMed ID: 36915997
[TBL] [Abstract] [Full Text] [Related]
4. ncRNA-mediated fatty acid metabolism reprogramming in HCC.
Xu K; Xia P; Chen X; Ma W; Yuan Y
Trends Endocrinol Metab; 2023 May; 34(5):278-291. PubMed ID: 36890041
[TBL] [Abstract] [Full Text] [Related]
5. AKR1C3-dependent lipid droplet formation confers hepatocellular carcinoma cell adaptability to targeted therapy.
Wu C; Dai C; Li X; Sun M; Chu H; Xuan Q; Yin Y; Fang C; Yang F; Jiang Z; Lv Q; He K; Qu Y; Zhao B; Cai K; Zhang S; Sun R; Xu G; Zhang L; Sun S; Liu Y
Theranostics; 2022; 12(18):7681-7698. PubMed ID: 36451864
[No Abstract] [Full Text] [Related]
6. Durable response to olaparib combined low-dose cisplatin in advanced hepatocellular carcinoma with fanca mutation: A case report.
Lai YH; Tung KC; Chen SC
Medicine (Baltimore); 2022 Sep; 101(39):e30719. PubMed ID: 36181052
[TBL] [Abstract] [Full Text] [Related]
7. Targeted delivery and anticancer effects of Chrysin-loaded chitosan-folic acid coated solid lipid nanoparticles in pancreatic malignant cells.
Farhadi A; Homayouni Tabrizi M; Sadeghi S; Vala D; Khosravi T
J Biomater Sci Polym Ed; 2023 Feb; 34(3):315-333. PubMed ID: 36063019
[TBL] [Abstract] [Full Text] [Related]
8. Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma.
Gong J; Thomassian S; Kim S; Gresham G; Moshayedi N; Ye JY; Yang JC; Jacobs JP; Lo S; Nissen N; Gaddam S; Tighiouart M; Osipov A; Hendifar A
Sci Rep; 2022 Sep; 12(1):15013. PubMed ID: 36056179
[TBL] [Abstract] [Full Text] [Related]
9. Study protocol of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with Oxaliplatin and 5-fluorouracil/Folinic acid followed by curative surgical resection in patients with hepatic Oligometastatic adenocarcinoma of the pancreas (HOLIPANC).
Gebauer F; Damanakis AI; Popp F; Quaas A; Kütting F; Lutz K; Held S; Deuß B; Göser T; Waldschmidt D; Bruns C
BMC Cancer; 2021 Nov; 21(1):1239. PubMed ID: 34794396
[TBL] [Abstract] [Full Text] [Related]
10. Systemic Therapy for Metastatic pancreatic cancer.
Ettrich TJ; Seufferlein T
Curr Treat Options Oncol; 2021 Oct; 22(11):106. PubMed ID: 34665339
[TBL] [Abstract] [Full Text] [Related]
11. Synchronization of Nanoparticle Sensitization and Radiosensitizing Chemotherapy through Cell Cycle Arrest Achieving Ultralow X-ray Dose Delivery to pancreatic Tumors.
Manoharan D; Chang LC; Wang LC; Shan YS; Lin FC; Wu LC; Sheu HS; Su WP; Yeh CS
ACS Nano; 2021 May; 15(5):9084-9100. PubMed ID: 33974409
[TBL] [Abstract] [Full Text] [Related]
12. Tailored adjuvant gemcitabine versus 5-fluorouracil/folinic acid based on hENT1 immunohistochemical staining in resected pancreatic ductal adenocarcinoma: A biomarker stratified prospective trial.
Shin DW; Lee JC; Kim J; Yoon YS; Han HS; Kim H; Hwang JH
Pancreatology; 2021 Jun; 21(4):796-804. PubMed ID: 33795193
[TBL] [Abstract] [Full Text] [Related]
13. Efficacy of chemotherapy combined with toripalimab in PD-L1-positive and high tumor mutation burden pancreatic acinar cell carcinoma: case report.
Xu H; Wang X; Zhou S; Hu Q; Cao D
Tumori; 2021 Dec; 107(6):NP24-NP27. PubMed ID: 33345750
[TBL] [Abstract] [Full Text] [Related]
14. Prognostic Significance of Plasma Fibrinogen/Serum Albumin Ratio in the Postoperative Outcome of pancreatic Ductal Adenocarcinoma.
Tomita K; Ochiai S; Gunji T; Hikita K; Kobayashi T; Sano T; Chiba N; Kawachi S
Anticancer Res; 2020 Dec; 40(12):7017-7023. PubMed ID: 33288597
[TBL] [Abstract] [Full Text] [Related]
15. Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment.
Fumet JD; Limagne E; Thibaudin M; Truntzer C; Bertaut A; Rederstorff E; Ghiringhelli F
BMC Cancer; 2020 Aug; 20(1):748. PubMed ID: 32778095
[TBL] [Abstract] [Full Text] [Related]
16. Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize treatment Selection.
Park W; Chen J; Chou JF; Varghese AM; Yu KH; Wong W; Capanu M; Balachandran V; McIntyre CA; El Dika I; Khalil DN; Harding JJ; Ghalehsari N; McKinnell Z; Chalasani SB; Makarov V; Selenica P; Pei X; Lecomte N; Kelsen DP; Abou-Alfa GK; Robson ME; Zhang L; Berger MF; Schultz N; Chan TA; Powell SN; Reis-Filho JS; Iacobuzio-Donahue CA; Riaz N; O'Reilly EM
Clin Cancer Res; 2020 Jul; 26(13):3239-3247. PubMed ID: 32444418
[TBL] [Abstract] [Full Text] [Related]
17. A systematic review and network meta-analysis of phase III randomised controlled trials for adjuvant therapy following resection of pancreatic ductal adenocarcinoma (PDAC).
Kamarajah SK; Bundred JR; Alrawashdeh W; Manas D; White SA
HPB (Oxford); 2020 May; 22(5):649-659. PubMed ID: 31894014
[TBL] [Abstract] [Full Text] [Related]
18. Detection of KRAS G12D point mutation level by anchor-like DNA electrochemical biosensor.
Zeng N; Xiang J
Talanta; 2019 Jun; 198():111-117. PubMed ID: 30876538
[TBL] [Abstract] [Full Text] [Related]
19. Targeted arsenite-loaded magnetic multifunctional nanoparticles for treatment of hepatocellular carcinoma.
Chi X; Zhang R; Zhao T; Gong X; Wei R; Yin Z; Lin H; Li D; Shan H; Gao J
Nanotechnology; 2019 Apr; 30(17):175101. PubMed ID: 30654348
[TBL] [Abstract] [Full Text] [Related]
20. Lipid profiling of pre-treatment plasma reveals biomarker candidates associated with response rates and hand-foot skin reactions in sorafenib-treated patients.
Saito K; Ikeda M; Kojima Y; Hosoi H; Saito Y; Kondo S
Cancer Chemother Pharmacol; 2018 Oct; 82(4):677-684. PubMed ID: 30062555
[TBL] [Abstract] [Full Text] [Related]
[Next]
